Article Figures & Data
Figures
- Figure 1 Study Concept
Patients were prospectively recruited by telephone call over a period of 15 consecutive week days. The baseline MG-ADL score and a blood sample to assess NP-IgG serology and IGRA was obtained before the first dose was administered. Seven days after the first dose, a second MG-ADL score was obtained. The second dose of the vaccine was administered 28 days after the first dose, following the manufacturer's recommendations. A third MG-ADL score was administered a week after the second dose. For all 3 MG-ADL scores, patients were asked about symptoms in the previous 7 days to score each MG-ADL item. A second blood sample was obtained 90 days after the second dose, and IGRA and spike-IgG were determined. During a 6-month-follow-up, COVID-19 symptoms were telematically assessed in all patients. COVID-19 = coronavirus disease 2019; IgG = immunoglobulin G; IGRA = interferon gamma release assay; MG-ADL = myasthenia gravis activities of daily living score; NP-IgG serology = SARS-CoV-2 nucleocapsid protein antibodies serology; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2; spike-IgG serology = SARS-CoV-2 spike protein 1 IgG antibodies serology.
- Figure 2 MG-ADL Score After Vaccination in Accordance With Baseline MG-ADL Score
Boxplot representing the MG-ADL scores after the first and second doses. The vertical axis represents the MG-ADL score reported by the patients, from minimum to maximum. The horizontal axis represents the MG-ADL score at baseline less than 3 (yellow box) or equal to or greater than 3 (orange box). At both time points, patients with an MG-ADL at baseline of 3 points or more had a higher MG-ADL score after each dose, with higher ranges reflecting greater variability in that group. MG-ADL score = myasthenia gravis activities of daily living score.
- Figure 3 Antispike-IgG Antibody titers and IGRA Positivity After Vaccinations According to Treatment Group
(A) Antispike-IgG antibody titers in IU/mL is represented in the dot plot for each treatment group. The mean titer is represented by a black line for each group. Threshold line represents the 5 IU/mL cutoff for positivity. (B) Blue bars indicate the percentage of IGRA-positive patients. The percentage of IGRA-negative patients is indicated in yellow bars. Indeterminate IGRA are represented in green bars. IGRA resulting in borderline tests are represented in purple bars. IgG = immunoglobulin G; IGRA = interferon gamma release assay; IST = immunosuppressant therapy.
Tables
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
